Product information:
| Product name |
Dydrogesterone Tablets |
| Storage |
Store in a dry place at 15 ºC - 30 ºC |
| Term of validity |
Sixty months. |
Pharmacology and Toxicology:
Didroxyprogesterone is an oral progesterone, which can make the endometrium into the complete secretory phase, thus preventing the risk of endometrial hyperplasia and canceration caused by estrogen. It can be used in various diseases with endogenous progesterone deficiency.
There were no effects of estrogen, androgen and adrenocortical hormone on didroprogesterone.
There was no fever and no effect on lipid metabolism.
Pharmacokinetics:
After oral administration, 63% of the labeled didroxyprogesterone was excreted in urine, and was completely removed in 72 hours. The main metabolite is DHD (20 α - dihydrogesterone), which is mostly determined by glucuronides in urine. The structure of all metabolites maintained the configuration of 4,6-dien-3-one without 17 α - hydroxylation, which determined that the product had no estrogenic and androgenic effects.
The plasma concentration of DHD was higher than that of the prototype drug after oral administration. The ratios of AUC and Cmax of DHD were 40 and 25, respectively.
After oral administration, didroxyprogesterone was absorbed rapidly, and the peak value of DHD and dydrogesterone reached (Tmax) at 0.5 and 2.5 hours, respectively.
The average final half lives of didroxyprogesterone and DHD were 5-7 hours and 14-17 hours, respectively.
Unlike endogenous progesterone, it is not excreted in the form of pregnanediol in urine. Therefore, the production of endogenous progesterone can still be measured according to the excretion of pregnanediol in urine.
indication:
It can be used to treat diseases caused by endogenous progesterone deficiency, such as
1.dysmenorrhea
2.endometriosis
3.secondary amenorrhea
4.irregular menstrual cycle
5.dysfunctional uterine bleeding
6.premenstrual syndrome
7.Threatened abortion or habitual abortion caused by progesterone deficiency
8.Infertility caused by luteal deficiency.
Taboo:
-Known to be allergic to the active ingredients of this product or any excipients.
-Progesterone dependent tumors are known or suspected.
-Vaginal bleeding of unknown origin;
-If it is used to prevent endometrial hyperplasia (for women who use estrogen), see contraindications for the combined use of estrogen and progesterone (e.g. didroprogesterone).
-Severe dysfunction: liver tumor (current or previous history), Dubin Johnson syndrome, potor syndrome, jaundice;
-Diseases or symptoms, such as severe pruritus, obstructive jaundice, herpes during pregnancy, porphyria and otosclerosis, are produced or aggravated during pregnancy or when sex hormones are used;
Audited Supplier 
){kind=link}